 SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, today announced that management plans to participate in four upcoming virtual investor conferences. 